Rapt Therapeutics AMENDMENT NO. 2 TO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTAnd Supply Agreement • March 7th, 2024 • RAPT Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment No. 2”) to the Agreement (as defined below), is entered into as of the date of last signature hereunder (“Amendment No. 2 Effective Date”), is by and among MSD International GmbH (“MSDIG”), MSD International Business GmbH (“MSDIB” and, collectively with MSDIG, “MSD”), each having a place of business at Tribschenstrasse 60, 6005 Luzern, Switzerland, and Rapt Therapeutics (‘RAPT”) having a place of business at 561 Eccles Avenue, South San Francisco, CA, 94080 MSD and RAPT are each referred to herein individually as a “Party” and, collectively, the “Parties”.
